ViRexx Presents Hepatitis C Chimigen'TM' Technology at Baculovirus & Insect Cell Culture Annual Meeting (Chronic Hepatitis C)

ViRexx Presents Hepatitis C Chimigen'TM' Technology at Baculovirus & Insect Cell Culture Annual Meeting
[Press Release] Business Wire via Yahoo! Finance - Feb 22 5:00 AM
EDMONTON, Alberta----Feb. 22, 2006--ViRexx Medical Corp. , a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that Rajan George, Ph.D., Vice President Research and Development of ViRexx, made a presentation about the Company's Chimigen technology for hepatitis C at the 9th Annual Meeting of the Save to My Web

Transition Therapeutics Announces Second Quarter Fiscal 2006 Financial Results
[Press Release] CNW Group via Yahoo! Finance - Feb 14 5:33 AM
Transition Therapeutics Inc. , a biopharmaceutical company focused on developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended December 31, 2005.Save to My Web

Monico Cup March 4 lineup submission deadline final
Sun Star - Feb 23 7:26 PM
THE deadline for the submission of lineups and requirements for teams participating in the 2006 Monico Cup Inter-Barangay Summer Basketball Tournament is definitely on Saturday, March 4.Save to My Web

Ashok Leyland's reserves set to go up on FCCB conversion
The Hindu - Feb 11 10:47 AM
COME March, Ashok Leyland will show a marked increase in its reserves, thanks to the conversion of its `foreign currency convertible bonds' (FCCB) into equity shares.Save to My Web

ViroPharma Announces Elimination of Debt
[Press Release] PR Newswire via Yahoo! Finance - 50 minutes ago
ViroPharma Incorporated announced today that it has eliminated its long-term debt in its entirety by redeeming the remaining $79 million principal amount of its 6% convertible subordinated notes due March 2007.Save to My Web